

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000624

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/43361 A (NOVONORDISK AS) 2 September 1999 (1999-09-02) claims 13-15 -----	1-31,34, 36-50, 53-55, 65,67-72
X	WO 99/43707 A (NOVONORDISK AS) 2 September 1999 (1999-09-02) claims 82-86 -----	1-31,34, 36-50, 53-55, 65,67-72
X	WO 99/43705 A (NOVONORDISK AS) 2 September 1999 (1999-09-02) claims 86-95 ----- -/-	1-31,34, 36-50, 53-55, 65,67-72

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 December 2004

Date of mailing of the international search report

-7 04 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dullaart, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000624

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/08872 A (NOVONORDISK AS ; KNUDSEN LISELOTTE BJERRE (DK); NIELSEN PER FRANKLIN ()) 5 March 1998 (1998-03-05) claims 6-12 -----	1-31,34, 36-50, 53-55, 65,67-72
X	KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664-1669, XP002201014 ISSN: 0022-2623 the whole document -----	1-31,34, 36-50, 53-55, 65,67-72
X	WO 01/51071 A (NOVO NORDISK AS) 19 July 2001 (2001-07-19) page 7, line 11 - line 19 -----	1-31,34, 36-50, 53-55, 65,67-72
X	WO 01/04156 A (LARSEN BJARNE DUE ; NEVE SOEREN (DK); MIKKELSEN JENS DAMSGAARD (DK); Z) 18 January 2001 (2001-01-18) page 31, line 5 - line 7 claims -----	1-31,34, 36-50, 53-55, 65,67-72
X	WO 99/43341 A (NOVONORDISK AS) 2 September 1999 (1999-09-02) page 17, line 12 - line 31 claims 13-15 -----	1-31,34, 36-50, 53-55, 65,67-72
P,X	HOLZ G G ET AL: "GLUCAGON-LIKE PEPTIDE-1 SYNTHETIC ANALOGS: NEW THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF DIABETES MELLITUS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 10, no. 22, November 2003 (2003-11), pages 2471-2483, XP009035149 ISSN: 0929-8673 the whole document -----	1-31,34, 36-50, 53-55, 65,67-72

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000624

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KURTZHALS P ET AL: "ALBUMIN BINDING OF INSULINS ACYLATED WITH FATTY ACIDS: CHARACTERIZATION OF THE LIGAND-PROTEIN INTERACTION AND CORRELATION BETWEEN BINDING AFFINITY AND TIMING OF THE INSULIN EFFECT IN VIVO" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 312, no. 3, 1995, pages 725-731, XP008005781 ISSN: 0264-6021 the whole document	1-31,34, 36-50, 53-55, 65,67-72
X	----- WO 02/058725 A (PF MEDICAMENT ; POWER ULTAN (FR); N GUYEN THIEN NGOC (FR)) 1 August 2002 (2002-08-01) example 1	1-31,34, 36-50, 53-55, 65,67-72
P,X	----- US 2004/001827 A1 (DENNIS MARK S) 1 January 2004 (2004-01-01) examples	1-31,34, 36-50, 53-55, 65,67-72
P,X	----- WO 03/087139 A (JAKUBOWSKI JOSEPH ANTHONY ; MCKINNEY THURMAN DWIGHT (US); LILLY CO ELI) 23 October 2003 (2003-10-23) page 12	1-31,34, 36-50, 53-55, 65,67-72
X	----- WO 03/002136 A (NOVO NORDISK AS) 9 January 2003 (2003-01-09) page 23, line 31 - page 24, line 25	1-31,34, 36-50, 53-55, 65,67-72
Y	----- DEACON C F ET AL: "DIPEPTIDYL PEPTIDASE IV RESISTANT ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 WHICH HAVE EXTENDED METABOLIC STABILITY AND IMPROVED BIOLOGICAL ACTIVITY" DIABETOLOGIA, BERLIN, DE, vol. 41, 1998, pages 271-278, XP000917648 ISSN: 0012-186X the whole document	1-31,34, 36-50, 53-55, 65,67-72
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000624

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SHEFFIELD W P: "Modification of clearance of therapeutic and potentially therapeutic proteins"</p> <p>CURRENT DRUG TARGETS - CARDIOVASCULAR AND HAEMATOLOGICAL DISORDERS, vol. 1, no. 1, June 2001 (2001-06), pages 1-22, XP002310970</p> <p>ISSN: 1568-0061</p> <p>page 4; table 1</p> <p>page 16, right-hand column, paragraph 3.3.3</p> <p>page 17, paragraph 5.0 - page 18</p>	1-31,34, 36-50, 53-55, 65,67-72
Y	<p>-----</p> <p>OSTROVSKII YU M: "COMPARATIVE CHARACTERISTICS OF THE HYDROPHOBIC NATURE OF CERTAIN PROTEINS BY THEIR INTERACTION WITH 2-P TOLUIDINO NAPHTHALENE-6-SULFONATE"</p> <p>UKRAYINS'KYI BIOKHMICHNYI ZHURNAL, vol. 47, no. 6, 1975, pages 701-707, XP008039733</p> <p>abstract</p> <p>tables 1,2</p>	1-31,34, 36-50, 53-55, 65,67-72
Y	<p>-----</p> <p>PICO G: "USE OF 1 ANILINO-8-NAPHTHALENESULFONATE AS A REPORTER MOLECULE TO STUDY THE BILE SALTS BOVINE SERUM ALBUMIN BINDING"</p> <p>STUDIA BIOPHYSICA, vol. 136, no. 1, 1990, pages 21-26, XP8039734</p> <p>ISSN: 0081-6337</p> <p>the whole document</p> <p>-----</p>	1-31,34, 36-50, 53-55, 65,67-72

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK2004/000624

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-31, 34, 36, 37-50, 53-55, 65, 67-72 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-31, 34, 36, 37-50, 53-55, 65,67-72 (all partially)

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is GLP-1

2. claims: 1-31, 34, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is exendin-4

3. claims: 1-31, 34, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is ZP-10

4. claims: 1-31, 34, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is GLP-2

5. claims: 1-31, 34, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is insulin

6. claims: 1-31, 34, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is growth hormone (GH)

7. claims: 1-31, 34, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is parathyroid hormone (PTH)

8. claims: 1-31, 34, 36, 37, 64-65, 67-69

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is FSH

9. claims: 1-31, 34, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is an alkylsulfonic acid group, and in which the therapeutic peptide is one of the remaining peptides mentioned in claim 66

10. claims: 1-32, 34, 36, 37-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is GLP-1

11. claims: 1-32, 34, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is exendin-4

12. claims: 1-32, 34, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is ZP-10

13. claims: 1-32, 34, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is GLP-2

14. claims: 1-32, 34, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is insulin

15. claims: 1-32, 34, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is GH

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

16. claims: 1-32, 34, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is PTH

17. claims: 1-32, 34, 36, 37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is FSH

18. claims: 1-32, 34, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is an alkylcarboxylic acid group, and in which the therapeutic peptide is one of the remaining peptides mentioned in claim 66

19. claims: 1-29, 31, 32, 34, 36, 37-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is GLP-1

20. claims: 1-29, 31, 32, 34, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is exendin-4

21. claims: 1-29, 31, 32, 34, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is ZP-10

22. claims: 1-29, 31, 32, 34, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is GLP-2

23. claims: 1-29, 31, 32, 34, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is insulin

24. claims: 1-29, 31, 32, 34, 36, 37, 62, 65, 67-69

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is GH

25. claims: 1-29, 31, 32, 34, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is PTH

26. claims: 1-29, 31, 32, 34, 36, 37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is FSH

27. claims: 1-29, 31, 32, 34, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is an alkyl group, and in which the therapeutic peptide is one of the remaining peptides mentioned in claim 66

28. claims: 1-29, 31, 33, 36-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is GLP-1

29. claims: 1-29, 31, 33, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is exendin-4

30. claims: 1-29, 31, 33, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is ZP-10

31. claims: 1-29, 31, 33, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is GLP-2

32. claims: 1-29, 31, 33, 36, 37, 60-61, 65, 67-69, 74

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is insulin

33. claims: 1-29, 31, 33, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is GH

34. claims: 1-29, 31, 33, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is PTH

35. claims: 1-29, 31, 33, 36, 37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is FSH

36. claims: 1-29, 31, 33, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is a cibacronyl group, and in which the therapeutic peptide is one of the remaining peptides mentioned in claim 66

37. claims: 1-29, 31, 36-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is GLP-1

38. claims: 1-29, 31, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is exendin-4

39. claims: 1-29, 31, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is ZP-10

40. claims: 1-29, 31, 36, 37, 56-59, 65, 67-69, 73

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is GLP-2

41. claims: 1-29, 31, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is insulin

42. claims: 1-29, 31, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is GH

43. claims: 1-29, 31, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is PTH

44. claims: 1-29, 31, 36, 37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is FSH

45. claims: 1-29, 31, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is the indolring-containing group shown in claim 55, and in which the therapeutic peptide is one of the further peptides mentioned in claim 66

46. claims: 1-29,31,36-50,53-55,65,67-72

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is GLP-1

47. claims: 1-29, 31, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is exendin-4

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

48. claims: 1-29, 31, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is ZP-10

49. claims: 1-29, 31, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is GLP-2

50. claims: 1-29, 31, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is insulin

51. claims: 1-29, 31, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is GH

52. claims: 1-29, 31, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is PTH

53. claims: 1-29, 31, 36, 37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is FSH

54. claims: 1-29, 31, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is the naphthalene-containing group shown in claim 55, and in which the therapeutic peptide is one of the remaining peptides mentioned in claim 66

55. claims: 1-29, 31, 36-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is GLP-1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

56. claims: 1-29, 31, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is exendin-4

57. claims: 1-29, 31, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is ZP-10

58. claims: 1-29, 31, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is GLP-2

59. claims: 1-29, 31, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is insulin

60. claims: 1-29, 31, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is GH

61. claims: 1-29, 31, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is PTH

62. claims: 1-29, 31, 36, 37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is FSH

63. claims: 1-29, 31, 36, 37, 65-69

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Relating to the conjugate as claimed, in which A is a perfluoroalkyl group, and in which the therapeutic peptide is one of the remainins peptides mentioned in claim 66

64. claims: 1-29, 31, 36-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is GLP-1

65. claims: 1-29, 31, 36, 37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is exendin-4

66. claims: 1-29, 31, 36, 37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is ZP-10

67. claims: 1-29, 31, 36, 37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is GLP-2

68. claims: 1-29, 31, 36, 37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is insulin

69. claims: 1-29, 31, 36, 37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is GH

70. claims: 1-29, 31, 36, 37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is a benzothienyl groupas shown in claim 55, and in which the therapeutic peptide is PTH

71. claims: 1-29, 31, 36, 37, 64-65, 67-69

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Relating to the conjugate as claimed, in which A is a benzothienyl group as shown in claim 55, and in which the therapeutic peptide is FSH

72. claims: 1-29, 31, 36, 37, 65-69

Relating to the conjugate as claimed, in which A is a benzothienyl group as shown in claim 55, and in which the therapeutic peptide is one of the remaining peptides mentioned in claim 66

73. claims: 1-25, 27-29, 31, 35-50, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an albumin binding peptide, and in which the therapeutic peptide is GLP-1

74. claims: 1-25, 27-29, 31, 35-37, 51, 53-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an albumin binding peptide, and in which the therapeutic peptide is exendin-4

75. claims: 1-25, 27-29, 31, 35-37, 52-55, 65, 67-72

Relating to the conjugate as claimed, in which A is an albumin binding peptide, and in which the therapeutic peptide is ZP-10

76. claims: 1-25, 27-29, 31, 35-37, 56-59, 65, 67-69, 73

Relating to the conjugate as claimed, in which A is an albumin binding peptide, and in which the therapeutic peptide is GLP-2

77. claims: 1-25, 27-29, 31, 35-37, 60-61, 65, 67-69, 74

Relating to the conjugate as claimed, in which A is an albumin binding peptide, and in which the therapeutic peptide is insulin

78. claims: 1-25, 27-29, 31, 35-37, 62, 65, 67-69

Relating to the conjugate as claimed, in which A is an albumin binding peptide, and in which the therapeutic peptide is GH

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

79. claims: 1-25, 27-29, 31, 35-37, 63, 65, 67-69

Relating to the conjugate as claimed, in which A is an
albumin binding peptide, and in which the therapeutic
peptide is PTH

80. claims: 1-25, 27-29, 31, 35-37, 64-65, 67-69

Relating to the conjugate as claimed, in which A is an
albumin binding peptide, and in which the therapeutic
peptide is FSH

81. claims: 1-25, 27-29, 31, 35-37, 65-69

Relating to the conjugate as claimed, in which A is an
albumin binding peptide, and in which the therapeutic
peptide is one of the remaining peptides mentioned in claim
66

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000624

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9943361	A	02-09-1999	AU 2712899 A	15-09-1999
			WO 9943361 A1	02-09-1999
			EP 1060192 A2	20-12-2000
			JP 2002504527 T	12-02-2002
			US 2004127418 A1	01-07-2004
			US 2002025933 A1	28-02-2002

WO 9943707	A	02-09-1999	AT 265224 T	15-05-2004
			AU 2610699 A	15-09-1999
			AU 2610799 A	15-09-1999
			AU 2610899 A	15-09-1999
			DE 69916811 D1	03-06-2004
			WO 9943706 A1	02-09-1999
			WO 9943341 A1	02-09-1999
			WO 9943707 A1	02-09-1999
			EP 1060191 A1	20-12-2000
			EP 1061946 A1	27-12-2000
			EP 1062240 A1	27-12-2000
			JP 2002504518 T	12-02-2002
			JP 2002512175 T	23-04-2002
			JP 2002506792 T	05-03-2002
			US 6268343 B1	31-07-2001
			US 2003199672 A1	23-10-2003
			US 2001011071 A1	02-08-2001
			ZA 9901569 A	27-08-1999
			ZA 9901570 A	02-09-1999

WO 9943705	A	02-09-1999	AU 2610599 A	15-09-1999
			WO 9943705 A1	02-09-1999
			EP 1056774 A1	06-12-2000
			JP 2002508162 T	19-03-2002
			US 6268343 B1	31-07-2001
			US 2003199672 A1	23-10-2003
			US 2001011071 A1	02-08-2001

WO 9808872	A	05-03-1998	AU 732957 B2	03-05-2001
			AU 3847897 A	19-03-1998
			AU 4112497 A	19-03-1998
			BR 9711437 A	18-01-2000
			CA 2264243 A1	05-03-1998
			CA 2468374 A1	05-03-1998
			CN 1232470 A	20-10-1999
			CZ 9900629 A3	14-07-1999
			WO 9808871 A1	05-03-1998
			WO 9808872 A1	05-03-1998
			EP 0944648 A1	29-09-1999
			EP 0929576 A1	21-07-1999
			HU 9903714 A2	28-03-2000
			JP 2000500505 T	18-01-2000
			JP 3149958 B2	26-03-2001
			JP 2000517308 T	26-12-2000
			JP 2001011095 A	16-01-2001
			KR 2000035964 A	26-06-2000
			MA 24129 A1	01-10-1997
			NO 990950 A	28-04-1999
			PL 331896 A1	16-08-1999
			RU 2214419 C2	20-10-2003
			US 6268343 B1	31-07-2001

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000624

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9808872	A	US 2003199672 A1	23-10-2003
		US 2001011071 A1	02-08-2001
		US 2004127418 A1	01-07-2004
		US 2002025933 A1	28-02-2002
		ZA 9707791 A	02-03-1998
		ZA 9707828 A	02-03-1998

WO 0151071	A 19-07-2001	AU 2353701 A	24-07-2001
		WO 0151071 A2	19-07-2001
		EP 1250126 A2	23-10-2002
		JP 2003519664 T	24-06-2003
		US 2001012829 A1	09-08-2001

WO 0104156	A 18-01-2001	EP 1076066 A1	14-02-2001
		EP 1196444 A1	17-04-2002
		EP 1329458 A2	23-07-2003
		AT 242267 T	15-06-2003
		AU 5966000 A	30-01-2001
		CA 2378431 A1	18-01-2001
		CN 1376166 A	23-10-2002
		DE 60003182 D1	10-07-2003
		DE 60003182 T2	06-05-2004
		WO 0104156 A1	18-01-2001
		DK 1196444 T3	29-09-2003
		ES 2200892 T3	16-03-2004
		JP 2003505347 T	12-02-2003
		NZ 517012 A	28-02-2003
		PT 1196444 T	31-10-2003
		US 2004106547 A1	03-06-2004
		US 6528486 B1	04-03-2003
		ZA 200200156 A	19-05-2003

WO 9943341	A 02-09-1999	AT 265224 T	15-05-2004
		AU 2610699 A	15-09-1999
		AU 2610799 A	15-09-1999
		AU 2610899 A	15-09-1999
		DE 69916811 D1	03-06-2004
		WO 9943706 A1	02-09-1999
		WO 9943341 A1	02-09-1999
		WO 9943707 A1	02-09-1999
		EP 1060191 A1	20-12-2000
		EP 1061946 A1	27-12-2000
		EP 1062240 A1	27-12-2000
		JP 2002504518 T	12-02-2002
		JP 2002512175 T	23-04-2002
		JP 2002506792 T	05-03-2002
		US 6268343 B1	31-07-2001
		US 2003199672 A1	23-10-2003
		US 2001011071 A1	02-08-2001
		ZA 9901569 A	27-08-1999
		ZA 9901570 A	02-09-1999

WO 02058725	A 01-08-2002	FR 2819810 A1	26-07-2002
		EP 1353690 A2	22-10-2003
		WO 02058725 A2	01-08-2002

US 2004001827	A1 01-01-2004	NONE	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK2004/000624

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03087139	A	23-10-2003	AU 2003220403 A1	27-10-2003
			CA 2480858 A1	23-10-2003
			EP 1496924 A2	19-01-2005
			HR 20040939 A2	31-12-2004
			WO 03087139 A2	23-10-2003

WO 03002136	A	09-01-2003	WO 03002136 A2	09-01-2003
			EP 1412384 A2	28-04-2004
			JP 2004535442 T	25-11-2004
			US 2003119734 A1	26-06-2003
